Cleo Diagnostics Ltd
Cleo Diagnostics Limited is an ovarian cancer diagnostics company.
The business
Cleo Diagnostics Limited is an ovarian cancer diagnostics company. Its principal activities involve the development and patent of a blood test for the detection of ovarian cancer. It focuses on bringing to market a blood test for the early diagnosis of ovarian cancer based on the novel CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is absent in non-malignant disease. It is advancing the availability of its blood test, under a modular execution strategy, which is designed to address all ovarian cancer detection markets with specific tests, including surgical triage, recurrence, high risk, and early-stage screening. Triage Test is a pre-surgical test to determine ovarian or adnexal mass for which surgical referral is required who have not yet been referred to an oncologist.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Market wrap: late market rally not enough to erase midweek losses
A late rally on Friday wasn’t enough for the Australian share market to recover from ground lost earlier in the week. Despite climbing 0.96% or 73.5 points on Friday, the ASX 200 gave up 0.42% for the week. Inflation still high Australia’s annual consumer inflation rate accelerated to 3.6% in April 2024, its highest level […]
Study shows Cleo Diagnostics’ ovarian cancer blood test outperforms current clinical benchmark
A benchmarking study comparing Cleo Diagnostics’ (ASX: COV) novel blood test for the accurate and early detection of ovarian cancer against conventional ultrasound options has been published in the scientific journal Cancers. The study compared the blood test with current standard clinical workflows that use cancer antigen 125 (CA125) testing and ultrasound to predict malignancy. […]
Cleo Diagnostics IPO raises $12 million to develop early-stage detection blood test for ovarian cancer
A novel and patented simple blood test which aims to detect ovarian cancer accurately and early, is the cornerstone of a successful $12 million initial public offering by medical technology company Cleo Diagnostics (ASX: COV). The Melbourne-based business is focused on advancing its patented and licenced technology development activities after issuing 60 million shares at […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.